Diligence memo · auto-generated · as of July 2, 2026
Tengion Inc
Tengion Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Tengion Inc operates in Biotechnology, based in WINSTON-SALEM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tengion Inc has raised $122M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $74M on 2013-06-28.
Most recent recorded round closed around 2013-06-28.
Valuation (modeled)modeled
Provath models Tengion Inc at approximately $3.0B (range $230M–$8.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.34× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (134% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 13.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 5.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Spark Therapeutics, Inc., X-Co Holdings, LP.
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.